These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31671265)

  • 1. Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates.
    Walker JA; Sorkin MR; Ledesma F; Kabaria SR; Barfield RM; Rabuka D; Alabi CA
    Bioconjug Chem; 2019 Nov; 30(11):2982-2988. PubMed ID: 31671265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
    Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
    Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
    Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
    Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
    Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
    Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
    Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
    ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Negative" Impact: The Role of Payload Charge in the Physicochemical Stability of Auristatin Antibody-Drug Conjugates.
    Johann F; Wöll S; Gieseler H
    J Pharm Sci; 2024 Aug; 113(8):2433-2442. PubMed ID: 38679233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
    Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
    Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation.
    Yang K; Chen B; Gianolio DA; Stefano JE; Busch M; Manning C; Alving K; Gregory RC; Brondyk WH; Miller RJ; Dhal PK
    Org Biomol Chem; 2019 Sep; 17(35):8115-8124. PubMed ID: 31460552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
    Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
    J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates.
    Levengood MR; Zhang X; Hunter JH; Emmerton KK; Miyamoto JB; Lewis TS; Senter PD
    Angew Chem Int Ed Engl; 2017 Jan; 56(3):733-737. PubMed ID: 27966822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates.
    Chen B; Gianolio DA; Stefano JE; Manning CM; Gregory RC; Busch MM; Brondyk WH; Miller RJ; Dhal PK
    ChemMedChem; 2018 Apr; 13(8):790-794. PubMed ID: 29517131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.